Top 20 Vaccines of 2025

Shots: Vaccines play a critical role in combating infectious diseases by stimulating antibody production and establishing immune memory. Biopharma companies around the globe continue to drive innovation in vaccine development, targeting both infectious and preventable diseases The global vaccine market was valued at $87.75B in 2024 and is projected to reach $151.96B by 2033, reflecting…

ByPrince GiriJuly 17, 2025

NEWS

GC Cell Partners with DAAN Biotherapeutics for Tumor Antigen-Specific Antibody Sequence

Shots:DAAN Biotherapeutics & GC Cell have entered into an exclusive technology transfer agreement for tumor antigen-specific antibody sequenceAs per the agreement, DAAN has granted GC Cell exclusive rights to use its antibody sequence, which targets a protein highly overexpressed in major solid tumors, for research & development of CAR-T & CAR-NK therapiesFinancial terms of…

ByRidhi RastogiApril 21, 2025

INSIGHTS+

Top Performing Drug – Ocrevus (July Edition)

Shots:In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, we bring for our readers a concise yet thorough analysis of the drug Ocrevus Ocrevus is a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis including CIS, RRMS, and SPMSPharmaShots presents…

BySenior EditorJuly 26, 2023

VIEWPOINTS

Olivier Harari, VP, Early Clinical Development at Regeneron Shares his Views on Pozelimab’s BLA Acceptance for the US FDA Priority Review

Shots:Olivier highlighted the P-II/III data based on which Regeneron’s BLA for Pozelimab was accepted by the US FDA under priority review to treat adults and children with CHAPLE diseaseCHAPLE disease is driven by an overactivation of the complement system due to CD55 deficiency. Pozelimab blocks the activity of complement factor C5 and prevents…

BySenior EditorJuly 17, 2023

VIEWPOINTS

John Orwin, President, and CEO at Atreca Shares his Views on Developing Novel Therapies for Cancer

Shots:John spoke about the development of a T cell engaging bispecific antibody directed against a novel solid tumor target under Atreca’s existing collaboration with XencorHe also talked about how this joint program combines the Atreca-discovered antibody, APN-346958, with Xencor’s XmAb CD3 bispecific antibody platformThe interview gives an understanding of Atreca’s focus on…

BySenior EditorJune 20, 2023

INSIGHTS+

Top Performing Drug of 2021 – Darzalex (March Edition)

Shots:The ongoing series of the top-performing drugs of 2021 based on revenue is continued by Darzalex as the top-performing drug for March monthDarzalex is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma in combination with different drugsThe report summarizes the key features of Darzalex including revenue…

BySenior EditorMarch 21, 2023

THOUGHTSPOT

Accelerating the Transition Between Antibody Research and Production

Speed is of the essence - while this statement may be somewhat worn thin, it is still - and particularly true in an industry that deals with developing and producing curative if not life-saving products. Especially fields such as biopharmacy and bioprocessing - both of which are fast-paced and seemingly reinventing themselves on a regular…

BySenior EditorJune 7, 2022